Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin

References

• Freeman SD, Kelm S, Barber EK, . Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005–2012.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Collins D, Fuller S, . Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice. Blood 1995;86:512–523.
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Hollander I, . Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13:47–58.
   PubMed Web of Science ®Google Scholar
• Ikemoto N, Kumar RA, Ling TT, . Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci USA 1995;92:10506–10510.
   PubMed Web of Science ®Google Scholar
• Stephen P, Kenneth K, Robert KS, . Preliminary results of Southwest Oncology Group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009;114(Suppl. 1): Abstract 790.
   Google Scholar
• Burnett AK, Hills RK, Milligan D, . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRCAML15 trial. Int J Oncol 2011;29:369–377.
   Web of Science ®Google Scholar
• Naito K, Takeshita A, Shigeno K, . Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000;14:1436–1443.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VH, . CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168–4170.
   PubMed Web of Science ®Google Scholar
• Walter RB, Raden BW, Hong TC, . Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003;102:1466–1473.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275–284.
   PubMed Web of Science ®Google Scholar
• Matsui H, Takeshita A, Naito K, . Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002;16:813–819.
   PubMed Web of Science ®Google Scholar
• Apostolidou E, Cortes J, Tsimberidou A, . Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887–891.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A, Cortes J, Thomas D, . Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33 + primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003;27:893–897.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A, Estey E, Cortes J, . Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;97:1481–1487.
   PubMed Web of Science ®Google Scholar
• Cianfriglia M, Mallano A, Ascione A, . Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol 2010;36:1513–1520.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Korth-Bradley J, Liu H, . Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001;41:1206–1214.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003;22:7496–7511.
   PubMed Web of Science ®Google Scholar
• Linenberger ML, Hong T, Flowers D, . Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988–994.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Onda K, Tanaka S, . Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol 2002;49:391–397.
   PubMed Web of Science ®Google Scholar
• Hall KS, Endresen L, Huitfeldt HS, . Induction of in vitro resistance to 4′-epidoxorubicin and cis-dichlorodiammineplatinum in hepatoma cells. Anticancer Res 1991;11:817–823.
   PubMed Web of Science ®Google Scholar
• Gekeler V, Frese G, Diddens H, . Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line. Biochem Biophys Res Commun 1988;155: 754–760.
   PubMed Web of Science ®Google Scholar
• Abolhoda A, Wilson AE, Ross H, . Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999;5:3352–3356.
   PubMed Web of Science ®Google Scholar
• Katayama K, Yoshioka S, Tsukahara S, . Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007;6:2092–2102.
   PubMed Web of Science ®Google Scholar
• Zhan M, Yu D, Liu J, . Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem 2005;280:4825–4833.
   Google Scholar
• Zhou J, Liu M, Aneja R, . Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006;66:445–452.
   PubMed Web of Science ®Google Scholar